Ardea's (RDEA) serendipitous gout drug RDEA594, which I wrote about here last year, is still alive. Phase IIb results had the compound meeting its endpoints (although not at the lowest dose), so on it goes to Phase III.
Since we've been talking all week around here about how Phase III is a different world, it's worth noticing that the primary endpoint is still a biomarker (reduction of serum urate levels), not a real clinical outcome. But in the case of gout, that association is probably strong enough to be optimistic. Good luck to 'em.